icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria †april 22-26
Back grey_arrow_rt.gif
 
 
 
Prevalence of Pretreatment NS5A and NS5B Resistance-Associated Variants and Genetic Variation Within HCV Subtypes Across Different Countries/Gilead-Study
 
 
  Reported By Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Evguenia S. Svarovskaia,1 Stefan Zeuzem,2 Charlotte Hedskog,1 Ross Martin,1 Diana M. Brainard,1 Michael D. Miller,1 Ed Gane,3 Hongmei Mo1 1Gilead Sciences, Inc., Foster City, California, USA; 2Goethe-Universitšt, Frankfurt am Main, Germany; 3Auckland Clinical Studies Ltd, Auckland, New Zealand

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

References
 
1. Messina JP, et al. Hepatology 2015;61:77-87;
2. Svarovskaia ES, et al. J Clin Microbiol 2012;50:3267-74;
3. Svarovskaia ES, et al. Clin Infect Dis 2014;59:1666-74;
4. Donaldson EF, et al. Hepatology 2015;61:56-65;
5. Zhdanov K, et al. APASL 2015, oral presentation.